HYDROCHLOROTHIAZIDE; IRBESARTAN | A202414 | MACLEODS PHARMACEUTICALS LTD
Highest NADAC/Unit
$0.1928
per ea
Lowest NADAC/Unit
$0.1676
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 33342005807IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB | $0.1928 | EA | Generic | — | 2026-06-17 |
| 33342005810IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB | $0.1928 | EA | Generic | — | 2026-06-17 |
| 33342005707IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB | $0.1676 | EA | Generic | — | 2026-06-17 |
| 33342005710IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB | $0.1676 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.